ClinicalTrials.Veeva

Menu

Dichotic Listening as a Predictor of Medication Response in Depression

N

New York State Psychiatric Institute

Status and phase

Completed
Phase 4

Conditions

Major Depressive Disorder
Dysthymia

Treatments

Drug: imipramine
Drug: escitalopram
Drug: bupropion

Study type

Interventional

Funder types

Other

Identifiers

NCT00404755
#5294R
IRB 5294R (Other Grant/Funding Number)

Details and patient eligibility

About

This study will recruit 100 depressed patients to test whether the previous finding of an association between treatment response (with treatment groups including placebo, imipramine, and fluoxetine) and preferences of hemispheric laterality in perceptual processing are also found with a different type of commonly used anti-depressant, bupropion.

Full description

Preliminary data suggest that depressed patients with increased left hemispheric laterality of perceptual processing are unlikely to improve during 6 weeks' treatment with placebo, while being very responsive to either imipramine or fluoxetine. Depressed patients who do not show evidence of poor right hemispheric functioning respond significantly more often to placebo than those with poor right hemispheric functioning , and do not show an advantage of drug over placebo. 100 patients will be tested with verbal and nonverbal dichotic tests, and then treated sequentially with bupropion, escitalopram, and imipramine. Preferential hemisphere for auditory processing will be correlated with treatment outcome.

Enrollment

17 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Ages between 18-65
  2. Meets Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) criteria for current Major Depression, Dysthymia or Depression Not Otherwise Specified

Exclusion criteria

  1. Known Hearing impairment
  2. Active suicidal ideation (history of suicide attempts will be evaluated on a case by case basis).
  3. Hamilton Rating Scale for Depression (HAMD), 21-item total score >20
  4. Current (past 6 months)alcohol and/or drug abuse or dependence
  5. Medical condition likely to require intervention contraindicated with study medication (e.g., known arrhythmia likely to be exacerbated by Imipramine)
  6. Bipolar I
  7. Psychosis
  8. Non-response to adequate trial of study medication (i.e., > or = 4 weeks on > or = bupropion 300mg/d, escitalopram 30mg/d, or imipramine 200mg/d)
  9. Premenopausal women not using known effective birth control
  10. Not currently depressed (whether considered due to current treatment or not)
  11. History of seizure, seizure disorder, anorexia nervosa, or bulimia
  12. Left-handed -

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

17 participants in 3 patient groups

escitalopram
Experimental group
Description:
escitalopram 10 mg/d for 1 week, then increasing by 10 mg/week if tolerated and not remitted to maximal dose of 40 mg/d
Treatment:
Drug: escitalopram
bupropion
Experimental group
Description:
bupropion extended release (XL) 150 mg/d for a week, then 300 mg/d for a week and then 450 mg/d; all dose increases if tolerated and not remitted
Treatment:
Drug: bupropion
imipramine
Experimental group
Description:
imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then by 50 mg/week to a maximum dose of 300 mg/d; all dose increases if tolerated and not remitted
Treatment:
Drug: imipramine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems